Navigation Links
Dmitry Medvedev Presented BIOCAD the First National "Industry" Award
Date:7/10/2014

ST. PETERSBURG, Russia, July 10, 2014 /PRNewswire/ --

On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD. The Company is developing a unique project called MabNext. Within the scope of MabNext project BIOCAD develops a number of innovative drugs based on monoclonal antibodies for treatment of cancer and autoimmune diseases. The ceremony took place at the International Exhibition "Innoprom 2014" in Ekaterinburg.

     (Logo: http://photos.prnewswire.com/prnh/20140514/686712)

     (Photo: http://photos.prnewswire.com/prnh/20140710/696843 )

According to the Russian Ministry of Health, in the last 12 years the number of new cases of malignant tumors has increased by 11%. The steady increase in the number of cancer patients is a global trend. According to the International Agency for Research on Cancer, in the next 20 years the number of new oncology patients in the world will reach the figure of 22 million cases per year.  Therefore, Russia and the rest of the world are so desperately in need of new effective drugs that will help to overcome serious illnesses and save millions of lives.

BIOCAD is developing a wide portfolio of innovative products based on monoclonal antibodies for treatment of diseases such as breast cancer, colorectal cancer, lung cancer, melanoma, multiple sclerosis, rheumatoid arthritis and psoriasis.

"Now the country is undergoing fundamental changes regarding availability of modern drugs for its people. Thanks to the support of Ministry of Industry and Trade, Ministry of Health, Ministry of Economic Development, Russian pharmaceutical companies are creating a powerful technologic basis for the production of innovative products and are competing successfully on the global pharmaceutical market. Of course, our foreign colleagues are not happy with this. However, now we can deliver innovative medicines that have no analogues in the world. The project MabNext is a bright example of this," said Dmitriy Morozov, CEO of BIOCAD.

The main advantage of products based on monoclonal antibodies, is that they affect only selected cells or molecules, in other words, these are targeted therapies.  Only relevant targets are neutralized without affecting the healthy cells.

BIOCAD has more than 10 of such innovative products based on monoclonal antibodies at different stages of development. One of the most noticeable ones is an antibody specific for interleukin 17. Clinical trials of this drug will begin in 2014. The drug has no analogues on the market and its characteristics are superior to anti-IL17 antibodies being developed by foreign companies. This product has huge potential when it comes to the treatment of socially significant diseases such as rheumatoid arthritis and psoriasis.

If we talk about cancer - the company is at the stage of developing original products based on monoclonal antibodies against targets such as PD-1, HER3, Ang-2 and others. Antibodies for PD-1 increase ability of patient's immune system to recognize and destroy tumor cells.


'/>"/>
SOURCE BIOCAD
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
2. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
3. Startling results in synthetic chemistry presented in Nature Chemistry
4. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
5. New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
6. Top Contenders For the First Annual 2012 Fright Night Awards Presented By Cancer Bites Announced
7. Promising Data Presented on GenVec Malaria Program
8. Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
9. Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
10. Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia
11. Data on the Selexis SUREtechnology Platform to be Presented at PEPTALK 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... (PRWEB) , ... May 18, 2017 , ... ... procedure on April 28, 2017 at the Prince Of Wales Private Hospital. The ... disc at level C6-C7. The patient failed conservative treatments prior to undergoing surgery. ...
(Date:5/18/2017)... ... May 17, 2017 , ... NDA Partners Chairman Carl Peck, MD , ... Advantar Laboratories and President of Pharmaceutical Development Business Unit of Cardinal Health, has joined ... Cardinal Health, he was former Chief Operating Officer at Anaborex, Senior VP and General ...
(Date:5/18/2017)... ... May 17, 2017 , ... USDM ... firm for the life sciences and healthcare industries, is honored that Jay ... Medical Devices conference in Brussels, Belgium. , Crowley played a crucial role in ...
(Date:5/18/2017)... ... May 17, 2017 , ... Many complicated ... likely to develop Alzheimer’s disease, while men are at greater risk for Parkinson’s ... neuronal bias is the aim of a research program at Worcester Polytechnic Institute ...
Breaking Biology Technology:
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, Sequencing.com will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
(Date:3/22/2017)... 21, 2017   Neurotechnology , a provider ... today announced the release of the SentiVeillance ... improved facial recognition using up to 10 surveillance, ... computer. The new version uses deep neural-network-based facial ... it utilizes a Graphing Processing Unit (GPU) for ...
Breaking Biology News(10 mins):